SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $17.71 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
SOPHiA GENETICS Stock Performance
NASDAQ:SOPH traded up $0.07 on Friday, hitting $3.67. The stock had a trading volume of 27,120 shares, compared to its average volume of 99,662. The business's 50-day simple moving average is $3.56 and its two-hundred day simple moving average is $3.55. The stock has a market cap of $239.93 million, a price-to-earnings ratio of -3.37 and a beta of 1.03. SOPHiA GENETICS has a 52-week low of $2.70 and a 52-week high of $7.37. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12.
Analyst Upgrades and Downgrades
Separately, Craig Hallum initiated coverage on shares of SOPHiA GENETICS in a report on Wednesday, December 18th. They issued a "buy" rating and a $11.00 price objective on the stock. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, SOPHiA GENETICS has a consensus rating of "Moderate Buy" and a consensus price target of $7.40.
Read Our Latest Research Report on SOPHiA GENETICS
About SOPHiA GENETICS
(
Get Free Report)
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
Featured Articles

Before you consider SOPHiA GENETICS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SOPHiA GENETICS wasn't on the list.
While SOPHiA GENETICS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.